PMH23 COST-EFFECTIVENESS OF OLANZAPINE VERSUS GENERIC RISPERIDONE AND OTHER ANTIPSYCHOTICS IN STANDARD ORAL FORMULATIONS IN PATIENTS WITH SCHIZOPHRENIA IN THE US
Nov 1, 2007, 00:00
10.1016/S1098-3015(10)65073-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)65073-5/fulltext
Title :
PMH23 COST-EFFECTIVENESS OF OLANZAPINE VERSUS GENERIC RISPERIDONE AND OTHER ANTIPSYCHOTICS IN STANDARD ORAL FORMULATIONS IN PATIENTS WITH SCHIZOPHRENIA IN THE US
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65073-5&doi=10.1016/S1098-3015(10)65073-5
First page :
Section Title :
Open access? :
No
Section Order :
231